减剂量与全剂量阿替普酶治疗急性肺栓塞的安全性和有效性:一项多中心观察性比较有效性研究
该多中心回顾性观察性比较有效性研究纳入接受全身阿替普酶的肺栓塞住院患者,全剂量组98例(100 mg),减剂量组186例(50 mg),采用倾向性评分加权调整基线特征。两组给药后休克指数、血压、心率、呼吸频率和 supplemental oxygen 需求均显著改善。减剂量组出血并发症低于全剂量组(13% vs. 24.5%,p=0.014),大出血(颅外)分别为1.1% vs. 6.1%(p=0.022)。倾向性评分加权后差异仍存在但未达统计学显著(15.4% vs. 24.7%,p=0.12;1.3% vs. 7.1%,p=0.067)。作者认为减剂量阿替普酶疗效相似且出血并发症更少,并建议考虑避免过度抗凝或侵入性操作以进一步减少并发症。
要点
- 减剂量阿替普酶(50 mg)组出血并发症13%,全剂量(100 mg)组24.5%(p=0.014),多为轻微出血。
- 大颅外出血减剂量组1.1% vs. 全剂量组6.1%(p=0.022);倾向性评分加权后为1.3% vs. 7.1%(p=0.067),未达统计学显著。
- 并发症相关因素包括超治疗水平肝素抗凝(37.5%的并发症病例)和侵入性操作(31.3%的并发症病例)。
- 倾向性评分加权后,两组死亡率、出院去向、ICU或住院时间及再入院率无显著差异。
适用人群与场景
- 住院的肺栓塞患者,接受全身阿替普酶治疗。
处置流程与药物剂量
- 全剂量方案:阿替普酶100 mg;减剂量方案:阿替普酶50 mg(给药途径原文未明确)。
研究设计与关键结果
- 多中心回顾性观察性比较有效性研究,纳入三级医院及15个社区和学术中心,全剂量组98例(100 mg),减剂量组186例(50 mg),采用倾向性评分加权调整基线特征。
- 给药后两组休克指数、血压、心率、呼吸频率和 supplemental oxygen 需求均显著改善。
- 出血并发症减剂量组13% vs. 全剂量组24.5%(p=0.014),多为轻微出血;大颅外出血1.1% vs. 6.1%(p=0.022);倾向性评分加权后出血并发症15.4% vs. 24.7%(p=0.12)和大颅外出血1.3% vs. 7.1%(p=0.067)差异未达统计学显著。
- 并发症与超治疗水平肝素抗凝相关者占37.5%,与侵入性操作相关者占31.3%。
- 倾向性评分加权后,死亡率、出院去向、ICU或住院时间及再入院率无显著差异。
证据类型、等级与局限
- 证据类型:多中心回顾性观察性比较有效性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与全剂量相比,减剂量阿替普酶可获得相似结局但出血并发症更少。
- 作者建议,应考虑避免过度抗凝水平或侵入性操作以进一步减少并发症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Systemic thrombolysis improves outcomes in patients with pulmonary embolism (PE) but is associated with the risk of hemorrhage. The data on efficacy and safety of reduced-dose alteplase are limited. The study objective was to compare the characteristics, outcomes, and complications of patients with PE treated with full- or reduced-dose alteplase regimens.
DESIGN: Multicenter retrospective observational study.
SETTING: Tertiary care hospital and 15 community and academic centers of a large healthcare system.
PATIENTS: Hospitalized patients with PE treated with systemic alteplase.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Pre- and post-alteplase hemodynamic and respiratory variables, patient outcomes, and complications were compared. Propensity score (PS) weighting was used to adjust for imbalances of baseline characteristics between reduced- and full-dose patients. Separate analyses were performed using the unweighted and weighted cohorts. Ninety-eight patients were treated with full-dose (100 mg) and 186 with reduced-dose (50 mg) regimens. Following alteplase, significant improvements in shock index, blood pressure, heart rate, respiratory rate, and supplemental oxygen requirements were observed in both groups. Hemorrhagic complications were lower with the reduced-dose compared with the full-dose regimen (13% vs. 24.5%, p = 0.014), and most were minor. Major extracranial hemorrhage occurred in 1.1% versus 6.1%, respectively ( p = 0.022). Complications were associated with supratherapeutic levels of heparin anticoagulation in 37.5% of cases and invasive procedures in 31.3% of cases. The differences in complications persisted after PS weighting (15.4% vs. 24.7%, p = 0.12 and 1.3% vs. 7.1%, p = 0.067), but did not reach statistical significance. There were no significant differences in mortality, discharge destination, ICU or hospital length of stay, or readmission after PS weighting.
CONCLUSIONS: In a retrospective, PS-weighted observational study, when compared with the full-dose, reduced-dose alteplase results in similar outcomes but fewer hemorrhagic complications. Avoidance of excessive levels of anticoagulation or invasive procedures should be considered to further reduce complications.
参考来源
- Melamed R, Tierney DM, Xia R, et al. Safety and Efficacy of Reduced-Dose Versus Full-Dose Alteplase for Acute Pulmonary Embolism: A Multicenter Observational Comparative Effectiveness Study. Crit Care Med. 2024. PMID: 38165776. doi:10.1097/CCM.0000000000006162
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。